Marco Racchi

Prof. Marco Racchi

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2005 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MVMarta Valenza
Marta Valenza
DRDorotea Rigamonti
Dorotea Rigamonti
DGDonato Goffredo
Donato Goffredo
CZChiara Zuccato
Chiara Zuccato
SFSimone Fenu
Simone Fenu
ECElena Cattaneo
Elena Cattaneo
The expansion of a polyglutamine tract in the ubiquitously expressed huntingtin protein causes Huntington's disease (HD), a dominantly inherited neurodegenerative disease. We show that the activity of the cholesterol biosynthetic pathway is altered in HD. In particular, the transcription of key genes of the cholesterol biosynthetic pathway is severely affectedin vivoin brain tissue from HD mice and in human postmortem striatal and cortical tissue; this molecular dysfunction is biologically relevant because cholesterol biosynthesis is reduced in cultured human HD cells, and total cholesterol mass is significantly decreased in the CNS of HD mice and in brain-derived ST14A cells in which the expression of mutant huntingtin has been turned on. The transcription of the genes of the cholesterol biosynthetic pathway is regulated via the activity of sterol regulatory element-binding proteins (SREBPs), and we found an ∼50% reduction in the amount of the active nuclear form of SREBP in HD cells and mouse brain tissue. As a consequence, mutant huntingtin reduces the transactivation of an SRE-luciferase construct even under conditions of SREBP overexpression or in the presence of an exogenous N-terminal active form of SREBP. Finally, the addition of exogenous cholesterol to striatal neurons expressing mutant huntingtin prevents their death in a dose-dependent manner. We conclude that the cholesterol biosynthetic pathway is impaired in HD cells, mice, and human subjects, and that the search for HD therapies should also consider cholesterol levels as both a potential target and disease biomarker.

1 October 2004 in Pharmacological Research
Verified
Journal Article
Closed access
MRMarco Racchi
Marco Racchi

26 October 2018 in Molecules
Verified
Journal Article
Open access
PDF file
MCMichele Catanzaro
Michele Catanzaro
Emanuela CorsiniEmanuela Corsini
Emanuela Corsini
MRMichela Rosini
Michela Rosini
MRMarco Racchi
Marco Racchi
Cristina LanniCristina Lanni
Cristina Lanni
The immune system is an efficient integrated network of cellular elements and chemicals developed to preserve the integrity of the organism against external insults and its correct functioning and balance are essential to avoid the occurrence of a great variety of disorders. To date, evidence from literature highlights an increase in immunological diseases and a great attention has been focused on the development of molecules able to modulate the immune response. There is an enormous global demand for new effective therapies and researchers are investigating new fields. One promising strategy is the use of herbal medicines as integrative, complementary and preventive therapy. The active components in medical plants have always been an important source of clinical therapeutics and the study of their molecular pharmacology is an enormous challenge since they offer a great chemical diversity with often multi-pharmacological activity. In this review, we mainly analysed the immunomodulatory/antinflammatory activity of Echinacea spp. and Curcuma longa, focusing on some issues of the phytochemical research and on new possible strategies to obtain novel agents to supplement the present therapies.

1 May 2000 in The FASEB Journal
Verified
Journal Article
Closed access
DSDaniela C. Solano
Daniela C. Solano
MSMarita Sironi
Marita Sironi
CBClaudia Bonfini
Claudia Bonfini
SSS. Bruno Solerte
S. Bruno Solerte
SGStefano Govoni
Stefano Govoni
MRMarco Racchi
Marco Racchi

1 July 1998 in Neurobiology of Disease
Verified
Journal Article
Open access
RERené Etcheberrigaray
René Etcheberrigaray
NHNaohide Hirashima
Naohide Hirashima
LNLinda Neec
Linda Neec
JPJosé Prince
José Prince
SGStefano Govoni
Stefano Govoni
DADaniel L. Alkon
Daniel L. Alkon
We have previously identified alterations of K+channel function, IP3-mediated calcium release, and Cp20 (a memory-associated GTP binding protein) in fibroblasts from Alzheimer's disease (AD) patients vs controls. Some of these alterations can be integrated into an index that distinguishes AD patients from controls with both high specificity and high sensitivity. We report here that alterations in IP3-mediated calcium responses are present in a large proportion of AD family members (i.e., individuals at high risk) before clinical symptoms of Alzheimer's disease are present. This was not the case if such members later “escaped” AD symptoms. This preclinical calcium signal correlate of later AD does not reflect, however, the presence of the PS1 familial AD gene.

11 December 2014 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
FPFederica Prati
Federica Prati
ASAngela De Simone
Angela De Simone
PBPaola Bisignano
Paola Bisignano
Andrea ArmirottiAndrea Armirotti
Andrea Armirotti
MSMaria Summa
Maria Summa
ACAndrea Cavalli
Andrea Cavalli